close
Add to watchlist
IsoRay Inc (ISR)
IsoRay, Inc. engages in the development, manufacture, and sale of isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. It primarily produces Proxcelan Cesium-131 brachytherapy seed for the treatment of prostate cancer and other solid tumor applications, such as breast, lung, liver, brain, and pancreatic cancer. Brachytherapy seeds are small devices used in an internal radiation therapy procedure. The company is headquartered in Richland, Washington.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.53 |
| Volume | 12262 |
| Volume Avg | 58412 |
| 52 Week High | 1.49 |
| 52 Week Low | 0.45 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.13 |
| EPS change Q/Q | -300% |
| EPS change Q/Q Yr ago | -20% |
| EPS change Q/Q next Q est | -33.33% |
| EPS change Y/Y | -28.57% |
| REV change Q/Q | 16.67% |
| REV change Q/Q Yr ago | 16.67% |
| EPS next Q est | -0.03 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |